For protocols exploring caloric restriction mimetics, mitochondrial aging, or NAD+ restoration therapies, AOD-9604 provides no mechanistic value
It offers natural healing benefits, supports faster recovery, and reduces discomfort, helping you get back to an active lifestyle
Different symptoms can develop differently in people, which requires personalization
Whats surprising is that B12 deficiency is very common and easy to miss
Discover Our Peptide Portfolio In 2023, the FDA reviewed several peptides nominated for compounding and placed many on the 503A Category 2 list.[3] Then in 2024, the agency cited limited clinical safety data, along with concerns about immunogenicity (how the immune system might respond) and dosing variability.[4] It was a precautionary decision, and precaution is an important part of regulatory oversight